App-Quantinova.ai

Effect of Certolizumab Pegol Over 48 Weeks on Signs and Symptoms in Patients with Psoriatic Arthritis with and without Prior Tumor Necrosis Factor Inhibitor Exposure

Michael Maldonado - Canadian Rheumatology Association (CRA) , 2014

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

Certolizumab pegol

Corticosteroid Use in Rheumatoid Arthritis Patients on Infliximab: Treatment Implications and Impact on Durability of Response Based on a Real-World Canadian Population

Algis Jovaisas - Canadian Rheumatology Association (CRA) , 2014

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Infliximab

Retention Rates and Effectiveness of Abatacept at 12 Months: A Subgroup Analysis of the Canadian Population from the ACTION Study

Coralie Poncet - Canadian Rheumatology Association (CRA) , 2014

Therapeutic Area

Disease

Drug/Treatment

N/A

Abatacept

Electronic Consent Processes for Rheumatology Research

Murray Baron - Canadian Rheumatology Association (CRA) , 2014

Therapeutic Area

Disease

Drug/Treatment

N/A

Correlation of Individual HAQ Questions with Outcome Measures in Rheumatoid Arthritis: Implications for Instrument Reduction

Majed Khraishi - Canadian Rheumatology Association (CRA) , 2014

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Infliximab

What are the Implications of Concomitant and Pre-medication on Infusion Reactions to Infliximab: Results from RemiTRAC Infusion, a Prospective Real-World Community Registry

Denis Choquette - Canadian Rheumatology Association (CRA) , 2014

Therapeutic Area

Disease

Drug/Treatment

N/A

Infliximab

Variability in Patient Characteristics and Outcomes in Rheumatoid Arthritis upon Infliximab Treatment Based on the Size of Biologic Treatment Registry Site

William Bensen - Canadian Rheumatology Association (CRA) , 2014

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Infliximab

Addressing Emotional Aspects of Living with Osteoarthritis as a Standard of Practice in the Osteoarthritis Therapeutic Education Program

Lorna Bain - Canadian Rheumatology Association (CRA) , 2014

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

N/A

Predictors of ACR/EULAR Boolean and SDAI Remission in Patients with Established Rheumatoid Arthritis Treated with Anti-TNF: An Analysis from the Prospective, Observational Registry, BioTRAC

Maqbool Sheriff - Canadian Rheumatology Association (CRA) , 2014

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ankylosing spondylitis

Infliximab

Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (52- Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase 3, Randomized, Controlled Trials

Phillip Mease - Canadian Rheumatology Association (CRA) , 2014

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

Sulfasalazine

Pseudohypoparathyroidism... a Possible Insight into the Pathophysiology of Ankylosing Spondylitis

Raj Carmona - Canadian Rheumatology Association (CRA) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Pseudohypoparathyroidism

N/A

Hypergammaglobulinemic Purpura of Waldenstrom an Underdiagnosed Condition with a Distinctive Clinical Rash

Edith Garneau - Canadian Rheumatology Association (CRA) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

B cell lymphomas

N/A

Development of Cardiovascular Quality Indicators (QIs) for Rheumatoid Arthritis (RA): Defining the Evidence Base and Identifying Candidate QIs

Deborah Marshall - Canadian Rheumatology Association (CRA) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Rheumatoid arthritis

Aspirin

Protective ERAP1 Variants Lead to Decreased Natural Killer Cell Conjugation and Chemokine Suppression

Zhenbo Zhang - Canadian Rheumatology Association (CRA) , 2014

Therapeutic Area

Disease

Drug/Treatment

N/A

A Systematic Review of Best Practices for Cardiovascular Disease Prevention in Persons with Rheumatoid Arthritis

Alexa Smith - Canadian Rheumatology Association (CRA) , 2014

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Change Over Time in the Profile of Ankylosing Spondylitis Patients Treated with Infliximab in Canadian Routine Care

Michael Starr - Canadian Rheumatology Association (CRA) , 2014

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ankylosing spondylitis

Infliximab

Efficacy of Ustekinumab in Patients with Active Psoriatic Arthritis : 9 Months Results

Eve Rioux - Canadian Rheumatology Association (CRA) , 2014

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

Ustekinumab

Which Patients with Low-Trauma Ankle Fractures are at Risk for Subsequent Fragility Fractures in the Optimus Cohort?

Mathieu Peladeau - Canadian Rheumatology Association (CRA) , 2014

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Osteoporosis

N/A

Does Ultrasound Examination Improve the Efficacy of Identifying PsA Patients with Erosive Arthritis?

Arane Thavaneswaran - Canadian Rheumatology Association (CRA) , 2014

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Erosive Disease

N/A

Improving Treatment Adherence Through Rapid Integrated Interdisciplinary Intervention after a Fragility Fracture: The OPTIMUS Initiative

Francois Cabana - Canadian Rheumatology Association (CRA) , 2014

Therapeutic Area

Disease

Drug/Treatment

N/A

Filters

28841 Abstracts